Literature DB >> 21529112

Bell's palsy associated with chronic HCV infection before and during peginterferon alfa and ribavirin therapy.

Hossain Jabbari1, Elham Fakharzadeh, Shahin Merat, Hedyeh Zamini, Amir Houshang Sharifi.   

Abstract

Neuropsychiatric side effects of peg interferon-α (PEG-IFN-α) therapy consist of a large spectrum of symptoms. Organic personality syndrome, organic affective syndrome, psychotic manifestations and seizures are more common side effects of PEG-IFN-α whereas cranial neuropathy and movement disorders are less common. Bell's palsy is often idiopathic, but has been linked to some viral infections, particularly with herpes viruses. Other infections, such as human immunodeficiency virus infection and Lyme disease, may also lead to idiopathic facial paralysis. Neither acute nor chronic Hepatitis C infection has been implicated previously in Bell's palsy, but PEG-IFN-α may play a role. Two patients with CHC who developed Bell's palsy before and during treatment with PEG-IFN-α and Ribavirin are presented here.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21529112     DOI: 011143/AIM.0013

Source DB:  PubMed          Journal:  Arch Iran Med        ISSN: 1029-2977            Impact factor:   1.354


  3 in total

Review 1.  Side effects of cytokines approved for therapy.

Authors:  Brian A Baldo
Journal:  Drug Saf       Date:  2014-11       Impact factor: 5.606

2.  Pegaferon in hepatitis C: Results of a Multicenter Study.

Authors:  Hossain Jabbari; Farhad Zamani; Khadijeh Hatami; Arghavan Sheikholeslami; Elham Fakharzadeh; Kiana Shahzamani; Hedye Zamini; Shahin Merat; Reza Malekzadeh; Amir Houshang Sharfi
Journal:  Middle East J Dig Dis       Date:  2011-09

3.  Chronic inflammation markers and cytokine-specific autoantibodies in Danish blood donors with restless legs syndrome.

Authors:  Joseph Dowsett; Maria Didriksen; Jakob Hjorth von Stemann; Margit Hørup Larsen; Lise Wegner Thørner; Erik Sørensen; Christian Erikstrup; Ole Birger Pedersen; Morten Bagge Hansen; Jesper Eugen-Olsen; Karina Banasik; Sisse Rye Ostrowski
Journal:  Sci Rep       Date:  2022-01-31       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.